Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 858 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Transforming optimism: finding new ways to treat rare cancers January 27, 2021 EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin June 19, 2026 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher...
